Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported equity compensation activity in the company’s ordinary shares. On February 5, 2026, he acquired 25,352 ordinary shares at no cost upon vesting of performance-vesting restricted stock units granted on February 23, 2023.
The vesting followed achievement of pre-set performance goals and application of a relative total shareholder return modifier, and represents the final vesting event under the 2023 PRSU awards. On the same date, 7,454 shares were disposed of at $33.55 per share (code F), typically indicating shares withheld or sold to cover tax obligations, leaving 75,638 shares held directly.
Alkermes plc executive David Joseph Gaffin reported equity compensation activity. On February 5, 2026, he acquired 25,352 ordinary shares at no cost when performance-vesting RSUs granted on February 23, 2023 vested after a three-year performance period ending December 31, 2025.
The same day, he disposed of 7,619 ordinary shares at $33.55 per share in a transaction coded “F.” After these transactions, he directly beneficially owned 223,107 ordinary shares of Alkermes plc.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported option exercises and share sales in Alkermes ordinary shares. On February 2, 2026, he exercised an employee stock option for 5,000 shares at an exercise price of $19.34, converting it into ordinary shares. The filing shows two same-day sales of ordinary shares: 5,000 shares sold at a weighted average price of $34.2449 and 4,000 shares sold at $33.54. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the reported trades, Hopkinson directly owns 57,740 ordinary shares and holds 26,356 employee stock options that are fully vested in accordance with their terms.
Alkermes plc director Shane Cooke reported exercising employee stock options and selling the resulting shares. On 02/02/2026, he exercised 61,200 employee stock options at an exercise price of $31.64 per share as the options approached their 02/28/2026 expiration.
That same day, he sold 29,087 ordinary shares at a weighted average price of $34.3382 per share and 32,113 ordinary shares at a weighted average price of $34.7796 per share in multiple transactions. After these trades, Cooke directly owned 103,744 ordinary shares of Alkermes plc.
The filing notes that the exercise and sale of expiring options were executed under a Rule 10b5-1 trading plan adopted on 02/27/2025, and that the options were fully vested in accordance with their terms.
A holder of Alkermes plc ordinary shares has filed a Rule 144 notice to sell 61,200 shares. The shares are to be sold through Merrill Lynch on NASDAQ, with an approximate sale date of 02/02/2026 and an aggregate market value of $2,115,674.45.
The 61,200 ordinary shares were acquired on 02/02/2026 through the exercise of employee stock options in a broker-assisted cashless exercise. The filing notes that 165,117,509 ordinary shares were outstanding, providing context for the size of the planned sale.
Alkermes plc insider Craig Hopkinson has filed a notice to sell ordinary shares under Rule 144. The filing covers 9,000 ordinary shares to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $305,384.28 and 165,117,509 shares outstanding.
The shares come from a broker-assisted cashless exercise of 5,000 employee stock options on 02/02/2026 and vesting of restricted stock unit awards totaling 4,000 shares during February 2025. The form also lists several prior ordinary share sales by Hopkinson over the past three months with disclosed gross proceeds.
Alkermes plc filed a current report describing a new corporate presentation it will use at the J.P. Morgan Healthcare Conference. The presentation, furnished as Exhibit 99.1, includes the company’s estimated total revenues for the year ended December 31, 2025. These revenue figures are described as preliminary, unaudited and subject to change once Alkermes completes its review of its 2025 financial statements.
The company notes that the information in Items 2.02 and 7.01, and in Exhibit 99.1, is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings unless specifically referenced.
Alkermes plc insider Craig Hopkinson has filed a Form 144 notice to sell ordinary shares. The filing covers 5,000 ordinary shares to be sold through Merrill Lynch on or about 01/08/2026 on NASDAQ, with an aggregate market value of $150,004.95. The filing notes 165,117,509 ordinary shares outstanding.
The 5,000 shares were acquired on 01/08/2025 through the exercise of employee stock options in a broker-assisted cashless exercise. The notice also lists prior sales over the past three months, including 9,000 ordinary shares sold on 10/15/2025 for gross proceeds of $283,776.70 and 9,000 shares sold on 11/03/2025 for $273,441.50, along with additional smaller transactions in December 2025 and early January 2026.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an options exercise and share sale. On 01/08/2026 he exercised an employee stock option for 5,000 ordinary shares at an exercise price of $19.34 per share and then sold 5,000 ordinary shares at a weighted average price of $30.001 per share, with individual sale prices ranging from $30.00 to $30.01.
Both the option exercise and the sale were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025, and the options exercised were fully vested in accordance with their terms. After these transactions, he directly owned 61,740 ordinary shares and 31,356 employee stock options.
Alkermes plc amended its agreement to acquire Avadel Pharmaceuticals, raising the cash offer from $18.50 to $21.00 per Avadel share, while keeping the potential additional $1.50 per share contingent value right unchanged. Alkermes also entered into an amended and restated senior secured bridge term loan facility of up to $1,512,562,923.28 to help fund the cash consideration and related fees and expenses for the Acquisition. The bridge loans, if drawn, will mature 364 days after funding and bear interest at either a Term SOFR-based rate plus 3.00% or an Alternate Base Rate plus 2.00%, with margin step-ups over time. Alkermes continues to expect completion of the Acquisition in the first quarter of 2026, subject to satisfaction or waiver of the stated conditions, and J.P. Morgan Securities LLC has confirmed sufficient resources are available to pay the cash consideration.